As patients criticise the decision not to approve breast cancer drug Kadcyla, [Executive MBA participant] Dr Rav Seeruthun, spokesman for drug company Roche, dismisses criticism of its high price, and damns the approval process.
Cambridge EMBA participant, Dr Rav Seeruthun, spokesman for drug company, Roche, defends the company’s pricing policy on breast cancer drug, Kadcyla.
Watch the video [channel4.com]
Brain food 
Compass 
Entrepreneurship 
In the media 
Network 
News 
Reasons why 
The lowdown 
Thinkers
Comments